Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITO-HF
jRCTs051240248Recruiting
- Sponsor
- Sumitomo Pharma
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of imeglimin in type 2 diabetes mellitus (T2DM) and chronic heart failure (CHF) (2 arms), sponsored by Sumitomo Pharma. Primary endpoint: Change from baseline in 99mTc-MIBI washout rate at 52 weeks. Started Apr 2025; status: recruiting.
02
Drugs
imeglimin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic heart failure (CHF)
Beyond the preview
Go deeper on jRCTs051240248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051240248.